Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference

·1 min read

NEW YORK, May 26, 2022--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Bernstein’s 38th Annual Strategic Decisions Conference in New York, New York on Thursday, June 2, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer and Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 8:00 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company’s presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005146/en/

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
investor.relations@bms.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting